Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Weekes CD, Rosen LS, Capasso A, Wong KM, Ye W, Anderson M, McCall B, Fredrickson J, Wakshull E, Eppler S, Shon-Nguyen Q, Desai R, Huseni M, Hegde PS, Pourmohamad T, Rhee I, Bessudo A.
Weekes CD, et al. Among authors: rosen ls.
Cancer Chemother Pharmacol. 2018 Aug;82(2):339-351. doi: 10.1007/s00280-018-3622-8. Epub 2018 Jun 15.
Cancer Chemother Pharmacol. 2018.
PMID: 29905898
Clinical Trial.